Lilly's Carole Ho talks blood tests for early Alzheimer's detection, the $2.8B AtaiBeckley psychedelics deal and Lilly's broader neuroscience push.
LONDON — Eli Lilly, the world’s biggest drugmaker, appears to be getting more ambitious about tackling brain diseases.
Last week, the company announced it would pay …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its…
Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in…
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
/C O R R E C T I O N -- Eli Lilly and Company/
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be…
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
